-- Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter and full year 2023, respectively --
-- Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in RYZUPTM and more than 1,000 patients initiating therapy through December 31 --
-- Signed Emisar (Optum Rx GPO) contract, all 3 PBM owned GPO contracts now finalized for 2024 --
-- Supplemental New Drug Application (sNDA) for LUMRYZ in the pediatric narcolepsy population accepted by FDA; approval decision expected in September 2024 --
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.